Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

European Urology Oncology（2023）

引用 0|浏览14

暂无评分

摘要

Pembrolizumab plus enzalutamide had limited antitumor activity in patients with abiraterone acetate–pretreated, chemotherapy-naive metastatic castration-resistant prostate cancer, with a safety profile consistent with the individual profile of each agent.

查看译文

关键词

Abiraterone acetate,Enzalutamide,Metastatic castration-resistant prostate cancer,Pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要